Get Free Access
TZ Ref No.: TZ-FFFFBB6
Tender Notice Urgent (6d left) 🌍 International (ICB) United States Healthcare and Medicine Pharmaceuticals Telecommunications

RNA sequencing and whole genome sequencing services

Doc ref no. 75N98027Q00043
Sector Healthcare and Medicine, Pharmaceuticals, Telecommunications
Publish Date 27 Oct 2026
Estimated Value Undisclosed
Tender Intelligence
Qualification analysis + key highlights for this procurement

TenderZenith matches this tender's eligibility criteria against your company profile to calculate a deterministic qualification score and identify potential disqualifiers.

A structured breakdown of scope, eligibility requirements, submission steps, and key conditions — extracted directly from the official notice.

Sign in to unlock Bid Fit & AI Opportunity Intelligence

TenderZenith calculates a personalized qualification score against your company profile and extracts structured intelligence from tender documents with your 7-Day Pro Trial (No Credit Card Required).

Description & Project Overview

NOTICE OF INTENT – SOLE-SOURCE ACQUISITION Notice No.: 75N98027Q00020 The National Institutes of Health (NIH), National Cancer Ibstitute (NCI), intends to award a Firm-Fixed-Price Purchase Order to Plasmidsaurus Inc. for RNA sequencing and whole genome sequencing services for various wild-type, drug-treated cell lines and samples related to CRISPR research. Description of the Requirement The primary objective of this study is to investigate common lymphoma-related translocations involving MYC, BCL6, or BCL2, while also examining copy number alterations and making CNV calls for genes of interest. To achieve this, RNA sequencing will be provided for samples generated in the Staudt laboratory. RNA sequencing is essential for characterizing genome edits and conducting transcriptomic analysis. By utilizing Plasmidsaurus, a faster and more scalable alternative to traditional sequencing methods based on the latest Oxford Nanopore Technologies platform, we aim to generate results that will deepen our understanding of cellular mechanisms involved in B-cell lymphoma and guide future downstream experiments. RNA sequencing and Whole-genome sequencing are required to observe the effects of various drugs on gene expression, identify pathways, and discover novel pathways. Justification for the Proposed Sole-Source Acquisition The Government intends to solicit from a single source pursuant to FAR 6.302-1, Only One Responsible Source and No Other Supplies or Services Will Satisfy Agency Requirements. Plasmidsaurus uses the latest Oxford Nanopore Technologies platform, a faster, more scalable alternative to traditional sequencing. Using the latest Oxford Nanopore Technologies platform ensures accurate sequencing, which is crucial for reproducible experiments which will significantly advance our understanding of, and treatment for, B-cell lymphoma, which is vital to cancer research at the National Cancer Institute. Response Information This notice is not a request for competitive quotations or proposals. However, interested parties that believe they can meet the Government's requirements may submit a capability statement demonstrating their ability to provide the required preventive maintenance and remedial repair services for the specified instrument and meet all applicable technical and operational requirements. The Government will review timely submissions to determine whether another responsible source is capable of satisfying the requirement and whether a competitive acquisition is appropriate. The Government anticipates making an award approximately five (5) calendar days after the closing date of this notice, unless the Government determines that another responsible source can satisfy the requirement. Capability statements must be submitted electronically to verne.griffin@nih.gov no later than 9:00 a.m. EDT on November 6, 2026. Please reference Notice No. 75N98027Q00043 in the subject line of the submission.

Days to Deadline
6 days
Closing: 05 Nov 2026, 18:00

Consortium & JV Partners

Matched
Need a Co-Bidder or Subcontractor?

Forming a Joint Venture increases technical eligibility and financial bonding capacity.

Post / Find JV Partners →

Key Procurement Details

Doc ref no. 75N98027Q00043
Notice Type Tender Notice
Bidding Type ICB
Publish Date 27 Oct 2026
Sector Healthcare and Medicine, Pharmaceuticals, Telecommunications
Document Fee Free
Bid Security Refer to documents
Funding Government Budget
Bid Opening Following deadline

Buyer Contact Information

HEALTH AND HUMAN SERVICES, DEPARTMENT OF / NATIONAL INSTITUTES OF HEALTH
LYNN GRIFFIN
6011 EXECUTIVE BLVD., SUITE 503L, BETHESDA, MD, 20892
United States